At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 272 enrolled
Drug / intervention
C21 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as add-on to Standard of Care in Adult Subjects With COVID-19
In Brief
A Phase 3 clinical trial evaluating C21 and Placebo for COVID-19. Completed, enrolled 272 participants across 60 sites in 10 countries.
Detailed Summary
This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm, multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add-on to standard of care (SoC) in adult subjects with COVID-19. The trial planned to enroll a total of maximum 300 randomized subjects, 150 per arm (oral C21 100 mg twice a day (BID) or placebo for 14 days) according to the 1:1 randomization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesArgentina, Brazil, Colombia, Czechia, India, Philippines, Russia, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartSep 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedMay 11, 2021
Enrollment StartSep 16, 2021
Primary CompletionApr 25, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.1 years ago
Interventions
C21drug
C21
Placebodrug
Placebo